1. Targeting the BRD4/FOXO3a/CDK6 axis sensitizes AKT inhibition in luminal breast cancer. Issue 1 (December 2018) Authors: Liu, Jingyi; Duan, Zhibing; Guo, Weijie; Zeng, Lei; Wu, Yadi; Chen, Yule; Tai, Fang; Wang, Yifan; Lin, Yiwei; Zhang, Qiang; He, Yanling; Deng, Jiong; Stewart, Rachel; Wang, Chi; Lin, Pengnian; Ghaffari, Saghi; Evers, B.; Liu, Suling; Zhou, Ming-Ming; Zhou, Binhua Journal: Nature communications Issue: Volume 9:Issue 1(2018) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phototesting in a case of encorafenib‐related photosensitivity. (12th July 2022) Authors: Claussen, C. S.; Mathes, S.; Li, L.; Evers, B.; Keshmiri, M.; Biedermann, T.; Posch, C.; Eberlein, B. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 36:Number 11(2022) Page Start: e934 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗